Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 260

1.

Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients.

Srivastava RM, Lee SC, Andrade Filho PA, Lord CA, Jie HB, Davidson HC, López-Albaitero A, Gibson SP, Gooding WE, Ferrone S, Ferris RL.

Clin Cancer Res. 2013 Apr 1;19(7):1858-72. doi: 10.1158/1078-0432.CCR-12-2426. Epub 2013 Feb 26.

PMID:
23444227
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

TLR8 stimulation enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells and dendritic cell cross-priming of EGFR-specific CD8+ T cells.

Stephenson RM, Lim CM, Matthews M, Dietsch G, Hershberg R, Ferris RL.

Cancer Immunol Immunother. 2013 Aug;62(8):1347-57. doi: 10.1007/s00262-013-1437-3. Epub 2013 May 18.

PMID:
23685782
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells.

López-Albaitero A, Lee SC, Morgan S, Grandis JR, Gooding WE, Ferrone S, Ferris RL.

Cancer Immunol Immunother. 2009 Nov;58(11):1853-64. doi: 10.1007/s00262-009-0697-4. Epub 2009 Mar 25.

PMID:
19319529
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines.

Luedke E, Jaime-Ramirez AC, Bhave N, Roda J, Choudhary MM, Kumar B, Teknos TN, Carson WE 3rd.

Surgery. 2012 Sep;152(3):431-40. doi: 10.1016/j.surg.2012.05.035. Epub 2012 Jul 6.

PMID:
22770960
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Natural killer (NK): dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity.

Lee SC, Srivastava RM, López-Albaitero A, Ferrone S, Ferris RL.

Immunol Res. 2011 Aug;50(2-3):248-54. doi: 10.1007/s12026-011-8231-0. Review.

PMID:
21717064
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

FcgammaRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck.

Taylor RJ, Chan SL, Wood A, Voskens CJ, Wolf JS, Lin W, Chapoval A, Schulze DH, Tian G, Strome SE.

Cancer Immunol Immunother. 2009 Jul;58(7):997-1006. doi: 10.1007/s00262-008-0613-3. Epub 2008 Nov 1. Erratum in: Cancer Immunol Immunother. 2009 Sep;58(9):1527-8.

PMID:
18979096
[PubMed - indexed for MEDLINE]
7.

Monocytes and the 38kDa-antigen of mycobacterium tuberculosis modulate natural killer cell activity and their cytolysis directed against ovarian cancer cell lines.

Gottschalk N, Lang S, Kimmig R, Singh M, Brandau S.

BMC Cancer. 2012 Oct 4;12:451. doi: 10.1186/1471-2407-12-451.

PMID:
23036052
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

TLR3 agonists improve the immunostimulatory potential of cetuximab against EGFR+ head and neck cancer cells.

Ming Lim C, Stephenson R, Salazar AM, Ferris RL.

Oncoimmunology. 2013 Jun 1;2(6):e24677. Epub 2013 Apr 29.

PMID:
23894722
[PubMed]
Free PMC Article
9.

IL-15 and IL-2 increase Cetuximab-mediated cellular cytotoxicity against triple negative breast cancer cell lines expressing EGFR.

Roberti MP, Barrio MM, Bravo AI, Rocca YS, Arriaga JM, Bianchini M, Mordoh J, Levy EM.

Breast Cancer Res Treat. 2011 Nov;130(2):465-75. doi: 10.1007/s10549-011-1360-2. Epub 2011 Feb 10.

PMID:
21308409
[PubMed - indexed for MEDLINE]
10.

Activation of tumor-promoting type 2 macrophages by EGFR-targeting antibody cetuximab.

Pander J, Heusinkveld M, van der Straaten T, Jordanova ES, Baak-Pablo R, Gelderblom H, Morreau H, van der Burg SH, Guchelaar HJ, van Hall T.

Clin Cancer Res. 2011 Sep 1;17(17):5668-73. doi: 10.1158/1078-0432.CCR-11-0239. Epub 2011 Jul 25.

PMID:
21788356
[PubMed - indexed for MEDLINE]
Free Article
11.

Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function.

Mailliard RB, Son YI, Redlinger R, Coates PT, Giermasz A, Morel PA, Storkus WJ, Kalinski P.

J Immunol. 2003 Sep 1;171(5):2366-73.

PMID:
12928383
[PubMed - indexed for MEDLINE]
Free Article
12.

Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK and gammadelta T cells.

Schnurr M, Scholz C, Rothenfusser S, Galambos P, Dauer M, Röbe J, Endres S, Eigler A.

Cancer Res. 2002 Apr 15;62(8):2347-52.

PMID:
11956095
[PubMed - indexed for MEDLINE]
Free Article
13.

The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines.

Roda JM, Joshi T, Butchar JP, McAlees JW, Lehman A, Tridandapani S, Carson WE 3rd.

Clin Cancer Res. 2007 Nov 1;13(21):6419-28. Epub 2007 Oct 25.

PMID:
17962339
[PubMed - indexed for MEDLINE]
Free Article
14.

Cetuximab ± chemotherapy enhances dendritic cell-mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen-specific cytotoxic T-cell response in vitro.

Correale P, Botta C, Cusi MG, Del Vecchio MT, De Santi MM, Gori Savellini G, Bestoso E, Apollinari S, Mannucci S, Marra M, Abbruzzese A, Aquino A, Turriziani M, Bonmassar L, Caraglia M, Tagliaferri P.

Int J Cancer. 2012 Apr 1;130(7):1577-89. doi: 10.1002/ijc.26181. Epub 2011 Aug 16.

PMID:
21618510
[PubMed - indexed for MEDLINE]
15.

Targeting CD137 enhances the efficacy of cetuximab.

Kohrt HE, Colevas AD, Houot R, Weiskopf K, Goldstein MJ, Lund P, Mueller A, Sagiv-Barfi I, Marabelle A, Lira R, Troutner E, Richards L, Rajapaska A, Hebb J, Chester C, Waller E, Ostashko A, Weng WK, Chen L, Czerwinski D, Fu YX, Sunwoo J, Levy R.

J Clin Invest. 2014 Jun 2;124(6):2668-82. doi: 10.1172/JCI73014. Epub 2014 May 16.

PMID:
24837434
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice.

Liu C, Lou Y, Lizée G, Qin H, Liu S, Rabinovich B, Kim GJ, Wang YH, Ye Y, Sikora AG, Overwijk WW, Liu YJ, Wang G, Hwu P.

J Clin Invest. 2008 Mar;118(3):1165-75. doi: 10.1172/JCI33583.

PMID:
18259609
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Dendritic cell-tumor coculturing vaccine can induce antitumor immunity through both NK and CTL interaction.

Kim KD, Choi SC, Kim A, Choe YK, Choe IS, Lim JS.

Int Immunopharmacol. 2001 Nov;1(12):2117-29.

PMID:
11710541
[PubMed - indexed for MEDLINE]
18.

Cetuximab-mediated tumor regression depends on innate and adaptive immune responses.

Yang X, Zhang X, Mortenson ED, Radkevich-Brown O, Wang Y, Fu YX.

Mol Ther. 2013 Jan;21(1):91-100. doi: 10.1038/mt.2012.184. Epub 2012 Sep 18.

PMID:
22990672
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Tumour antigen targeted monoclonal antibodies incorporating a novel multimerisation domain significantly enhance antibody dependent cellular cytotoxicity against colon cancer.

Jain A, Poonia B, So EC, Vyzasatya R, Burch EE, Olsen HS, Mérigeon EY, Block DS, Zhang X, Schulze DH, Hanna NN, Twadell WS, Yfantis HG, Chan SL, Cai L, Strome SE.

Eur J Cancer. 2013 Oct;49(15):3344-52. doi: 10.1016/j.ejca.2013.06.009. Epub 2013 Jul 18.

PMID:
23871153
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk